Abstract
Several novel 6-thio-3-R-2-oxo-2H- [1, 2, 4] triazino [2,3-c] quinazoline-based compounds containing an ω-(dialkylamino(heterocyclyl)]alkyl fragment were synthesized to examine their anticancer activity. Some of the 6-{[ω-(heterocyclyl)alkyl]thio}-3-R-2H- [1, 2, 4] triazino [2,3-c] quinazoline-2-ones (3.1-3.10) were obtained by the nucleophilic substitution of 6-[ω-halogenalkyl]thio-3-R-2H- [1, 2, 4] triazino [2,3-c] quinazoline-2-ones (2.1-2.8) with azaheterocycles. Alternatively, compounds 3.1-3. 22 were synthesized by alkylation of 3-R-6-thio-2Н- [1, 2, 4] triazino [2,3-c] quinazoline-2-ones potassium salts (1.1-1.4) with (2-chloroethyl)-N,N-dialkylamine hydrochlorides or 1-(2-chloroethyl)heterocycle hydrochlorides. The structures of compounds were elucidated by 1 H, 13 C NMR, LC-MS and EI-MS analysis. Then anticancer and antibacterial, bioluminescence inhibition of Photobacterium leiognathi Sh1 activities of the substances were tested in vitro. It was found that compound 3.18 possessed a wide range of anticancer activity against 27 cell lines of cancer: non-small cell lung, сolon, CNS, ovarian, renal, prostate, breast, melanoma and leukemia (log GI 50
Introduction
The quinazoline skeleton is a heterocyclic system that can be found in many prospective anticancer drugs [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Some derivatives, notably 4-R-phenylaminoquinazolines (drugs «Iressa» (I), «Erlotinib» (II), «Vandetanib» (III) and others) are ATP-competitive irreversible inhibitors of the tyrosine-kinase epidermal growth factor receptor and others protein-kinase enzymes, which are widely used in oncological practice (Scheme 1) [3, 5] . It's important that anticancer activity of 4-R-phenylaminoquinazolines is determined by both the base heterocycle and aniline fragment in 4 th position of molecule and requires the presence of halogens, hydroxy and cyano group. To improve the pharmacokinetic properties, notably bioavailability and lipophilicity, it is advisable to introduce appropriate functional groups in 6 th and 7 th position of molecule. Such anintroduction of acryl-or butyn-2-amide fragments leads to the increase of metabolism and elimination and decrease of accumulation, while methoxy-and heterocyclylalkyloxy-groups are necessary for the improvement of hydrophobic interaction with the appropriate enzymes.
The variants of annelation or introduction of different heterocyclic pharmacophores to quinazoline skeleton were described recently. [18] [19] [20] [21] . Thus, [1, 2, 4] triazino [2,3-c] quinazoline (IV) is a product of annelation of quinazoline to triazine system, and from the view of medicinal chemistry optimization is undoubtedly an optimal target for anticancer drugs design. So, it is possible to modify the above mentioned molecule at the 3rd position of triazine system, the 6th position of pyrimidine, and the 8th-11th positions of benzene ring. In previous work we've made an attempt to modify structure (IV) at the 3rd (V) and 6th (VI, VII) positions [18] [19] [20] [21] [22] . Hence, 3-R-6-thioxo-6,7-dihydro-2H- [1, 2, 4] triazino [2,3-c] quinazolin-2-one (VI) is a promising "lead-compound" to combine with dialkylamino(heterocyclyl)alkyl substituent for development of the potent chemotherapeutic agents.
Results and discussion

Chemistry
The known synthetic methods of ω-dialkylamino(heteryl)alkylthioheterocyclic fragment formation are based on two main approaches: the first approach is the interaction of ω-halogenalkylthioheteryles with the excess of secondary amines in anhydrous medium, and the second approach is the direct alkylation of heterylthiones by ω-dialkylaminoalkylhalogenes or 1-(ω-halogenoalkyl)heterocyclyles in organic solvents with the presence of organic or inorganic base. Alkylation of substances 1.1-1.4 by symmetrical and asymmetrical dihalogenalkanes was investigated to fulfill the first approach. According to the LC-MS data, refluxing the substances 1.1-1.2 with 1,2-dibromoethane for 10-20 min in water-alcohol solution led to the mixture of substances 2.1, 2.2 (up to 90%) with appropriate bisderivatives (4-8%) and starting substances (up to 2-6%). The treatment of compounds 1.3-1.4 with asymmetrical dihalogenalkanes under mentioned conditions yielded 90% of substances 2.1-2.8. When synthesis proceeded longer (up to 60 min) in anhydrous environment (propanol-2, dioxane), that led to less of a yield (up to 60%) with an increase in the amount of bisderivatives (up to 20-40%). The latter effect was caused by the low solubility of potassium salts 1.1-1.4 in anhydrous solvents. It's important that substances 2.1-2.8 were easily purified by recrystallisation from ethanol or propan-2-ol.
Refluxing of the 6-[ω-halogenalkyl]thio-3-R-2H- [1, 2, 4] triazino [2,3-c] quinazoline-2-ones (2.1-2.8) with the proper equimolar amount of heterocycles (pyrrolidine, piperidine, morpholine) in dioxane with potassium iodide, further neutralizing the obtained hydro-chlorides by sodium hydrocarbonate and extraction of substances with chloroform effected the lessening of yields (10-20%) of compounds 3.1-3.10 (Scheme 2). Products were quite easily and strongly oxidized in such conditions (reaction mixture became dark brown) that had a substantial influence on the purity of compounds 3.1-3.10. Replacement of solvent by ethanol or propan-2-ol and prolongation of reaction didn't influence the increasing of substances yields. It was found that the product's yields and purity could be improved by the addition of the excess heterocycles and refluxing in propan-2-ol-water mixture. Additionally, the obtained amines 3.1-3.10 could be easily extracted from reaction mixture with diethyl ether or chloroform after poured into water. The 3-R-6-thio-6,7dihydro-2H- [1, 2, 4] triazino [2,3-c] quinazoline-2-ones (1.1-1.4) potassium salts were alkylated with (2-chloroethyl)-N,N-dialkylamines hydrochlorides or 1-(2-chloroethyl)heterocycles hydrochlorides in the presence of triethylamine to fulfill the second approach (Scheme 3). The water-propan-2-ol reaction medium provided the higher yields of resulting products 3.1-3.3, 3.11-3.22.
R = CH
The individuality and structure of synthesized substances were confirmed by their IR, 1 H, 13 C NMR, and EI-MS data. In IR spectra the triazinoquinazoline system was characterized by: ν С=О (1759-1658 сm −1 ), ν C-C (1520сm + with m/z 103 (27.3-10.5%) in the result of the С(2) -С(3) and N(3) -N(4) bonds cleavage of triazinoquinazoline system [18] [19] [20] .
Pharmacology and structure-activity relationship
Bioluminescence inhibition test
The results of bioluminescence research showed that the majority of compounds appeared to be toxic for bacteria Photobacterium leiognathi Sh1 (Table 1) 
Antimicrobial and antifungal activities
The results of antimicrobial screening showed that researched substances had significant antimicrobial activity only against cereous bacteria Mycobacterium luteum ( 3) antimicrobial activity against M. luteum is characteristic for the majority of compounds, and compounds with phenyl, thionyl or р-methoxyphenyl substituents at 3rd position have the strongest activity.
3.11-3.22) had the highest antimicrobial activity against M. luteum, testifying the potential presence of antituberculosis activity of the mentioned compounds.
Anticancer assay for preliminary in vitro testing
Newly synthesized compounds were selected by the National Cancer Institute (NCI) Developmental Therapeutic Program for the in vitro cell line screening to investigate their anticancer activity. Table 3 .
Investigation of the compounds 3.1, 3.14-3.16, 3.18, 3.21 showed that individual cell lines had different sensitivity towards synthesized compounds in concentration 10 −5 М (Table 3) . Thus, substance 3.1 exhibited cytotoxicity against cell lines of leukemia (CCRF-CEM, HL-60(TB)). Change the phenyl substituent in position 3 (3.1) by methyl led to the substantial reduction of activity against cell lines of leukemia. Synthesized compounds that had at the 3rd position р-methoxyphenyl and р-methylphenyl (3.21) group possessed strong cytotoxicity against the majority of the cancer cell lines. It is interesting that the significant antiproliferative activity was characteristic for compound 3.18 against leukemia cell lines (K-562, MOLT-4, RPMI-8226, SR), non-small cell lung cancer (A549/ATCC, HOP-62, HOP-92, NCI-H322M, NCI-H460), colon cancer (COLO 205, HCT-116, HCT-15, HT29, KM12, SW-620), CNS cancer (SF-539, U251), melanoma (LOX IMVI, MALME-3M), ovarian cancer (IGROV1, OVCAR-3, OVCAR-4, OVCAR-8, NCI/ADR-RES), renal cancer (ACHN, RXF 393, SN12C, UO-31), prostate cancer (PC-3, DU-145) and breast cancer (MCF7, MDA-MB-231/ATCC). Furthermore, compounds 3.1, 3.14, 3.18 showed antitumor activity, notably 3.1 against leukemia cell lines (CCRF-CEM, HL-60(TB)), 3.14 -against leukemia SR, 3.18 -against leukemia SR and non-small cell lung cancer (A549/ATCC, NCI-H460).
Tab. 3.
Cytotoxic activity of the compounds in conc. The dose-dependent action in 5 concentrations according to standard procedure of NCI (100μM-0.01μM) was researched for 3.14, 3.16, 3.18. The 3 dose-dependent parameters were calculated: 1) GI 50 -molar concentration of the compound that inhibits 50% net cell growth; 2) TGI -molar concentration of the compound leading to total inhibition of cell growth; 3) LC 50 -molar concentration of the compound leading to 50% net cell death. If logarithmic data of researched parameters (log GI 50 , log TGI та log LC 50 ) was less than −4.00, substances were marked as active. For each of the parameters the average experimental data were calculated (mean graph midpoints, MG_MID) ( It is important to note that compound 3.14 had the highest anticancer activity against cell 2) substituent at the 3rd position with increasing activity in the range of Me<Ph<4-MePh<4-MeOPh;
3) substituents at the 6th position, namely dialkylamino(heterocyclil)alkyl fragment connected by Sulphur with heterocyclic system, gaining the activity in range of Me<i-Pr<Pyr<Et. Thus, it is interesting to modify the «lead-compounds» among the [1, 2, 4] triazino [2,3-c] quinazoline derivatives for further pharmacological investigations.
COMPARE analysis and molecular mechanism assumptions
We have also performed COMPARE analyses for all the active compounds to investigate the similarity of their cytotoxicity (mean graph fingerprints) with those of known anticancer standard agents, NCI active synthetic compounds and natural extracts, which are present in public available databases [29] [30] [31] [32] . Such analysis is based on comparing the patterns of differential growth inhibition for cultured cell lines and can potentially gain insight into the mechanism of the cytotoxic action. It determines Pearson correlation coefficient (PCC) for the degree of similarity of mean graph fingerprints obtained from in vitro anticancer screen with patterns of activity of standard agents. We performed COMPARE computations for synthesized compounds against the NCI 'Standard Agents' database at the GI 50 level (correlations PCC >0.4) ( Table 6 ).
COMPARE analysis hypothesis precludes that the compounds 3.14, 3.16 and 3.18 might have the same mechanism of action as the agent with known action mechanism, if the data pattern of a compound correlates well with the data pattern of compounds belonging to the standard agent database. The majority of significant correlations for 3-R-6-thio-2H- [1, 2, 4] triazino [2,3-c] quinazoline-2-ones derivatives were found with inhibitor of topoisomerases I and II, as well as inhibition or promotion of microtubules polymerization and CTP-synthase inhibitor. These molecular targets should be considered as the first priority and be explored for the leukemia, colon, CNS, renal cancers cell lines.
Experimental
Chemistry
General methods
Melting points were determined in open capillary tubes and were uncorrected. The elemental analyses (C, H, N, S) were performed using the ELEMENTAR vario EL Cube analyzer (USA). Analyses were indicated by the symbols of the elements or functions within ±0.3% of the theoretical values. IR spectra (4000-600 cm -1 ) were recorded on a Bruker ALPHA FT-IR spectrometer (Bruker Bioscience, Germany) using a module for measuring attenuated total reflection (ATR).
1 H NMR spectra (500 MHz) and 13 C NMR spectra (100 MHz): were recorded on a Varian-Mercury 400 (Varian Inc., Palo Alto, CA, USA) spectrometers with TMS as internal standard in DMSO-d 6 solution. LC-MS were recorded using chromatography / mass spectrometric system which consists of high performance liquid chromatograph «Agilent 1100 Series» (Agilent, Palo Alto, CA, USA) equipped with diode-matrix and mass-selective detector «Agilent LC/MSD SL» (atmospheric pressure chemical ionization -APCI). Electron impact mass spectra (EI-MS) were recorded on a Varian 1200 L instrument at 70 eV (Varian, USA). The purity of all obtained compounds was checked by 1 H-NMR and LC-MS. 4 were synthesized according to the reported procedures [18, 21] . Other starting materials and solvents were obtained from commercially available sources and used without additional purification. 6-[(ω-halogenoalkyl)thio)-3-R-2H-[1,2,4]triazino-[2,3-c]quinazolin-2-ones (2.1-2.8) .
General procedure for synthesis of
To a 0.01 M solution of 3-R-6-thio-6,7dihydro-2H-[1,2,4]triazino[2,3-c]quinazoline-2-one potassium salt (1.1-1.4 ) in 20 ml of propan-2-ol-water mixture (5:1) was added a solution of 0.01 M of 1,2-dibromoethane, 1-bromo-3-chloropropane or 1-bromo-4-chlorobutane in 10 ml of propan-2-ol. Reaction mixture was heated for 10-20 min, cooled, precipitate was filtered and dried. Formed precipitates were recrystallized from ethanole and propan-2-ol. [1, 2, 4] triazino [2,3- [2,3- [1, 2, 4] triazino [2,3- [1, 2, 4] triazino [2,3- [1, 2, 4] triazino [2,3-c] [1, 2, 4] triazino [2,3- [1, 2, 4] triazino [2,3- [1, 2, 4] triazino [2,3- [1, 2, 4] triazino [2,3-c] quinazolin-2-ones (3.1-3.22) . [1, 2, 4] triazino [2,3- [1, 2, 4] triazino [2,3- cultivated in a nutrient environment containing (g/L): pepton -5, yeast extract -1.5, meat extract -1.5, sodium chloride -30, pH = 7.4. In the acute action test (inhibiting luminescence of bacteria), bacteria were diluted with the 3% sodium chloride solution down to a concentration of 10 5 cells/mL. 5-50 mg/mL of the studied substances suspended in DMSO were mixed with 1 mL of the diluted bacterial suspension. Vials were incubated for 10 min at 25°C, then, the intensity of bioluminescence was measured in percent (%) relative to the controls, which were prepared without the studied compounds. In the chronic action test (inhibiting growth and luminescence of bacteria), growth medium was added for potential breeding in a ratio of 1:50 and the mix was incubated for 16-18 h at 30°C, whereupon the intensity of bioluminescence was measured the same way as in acute action testing. Tetracycline was used as a reference. The bacterial luminescence was measured with a Bioluminometer BLM-8801 («Science», Krasnoyarsk, Russia).
6-[(2-Bromoethyl)thio]-3-methyl-2H-
6-[(2-Bromoethyl)thio]-3-phenyl-2H-[1,2,4]triazino
6-[(3-Chloropropyl)thio]-3-methyl-2H-
6-[(3-Chloropropyl)thio]-3-phenyl-2H-
6-[(3-Chloropropyl)thio]-3-(4-methylphenyl)-2H-
6-[(3-Chloropropyl)thio]-3-(4-methoxyphenyl)-2H-
6-[(3-Chlorobutyl)thio]-3-methyl-2H-
6-[(3-Chlorobutyl)thio]-3-phenyl-2H-
General procedure for synthesis of 6-[(ω-dialkylamino(heterocyclyl-)alkyl)thio]-3-R-2H-
3-Phenyl-6-[(2-pyrrolidin-1-ylethyl)thio]-2H-
3-Phenyl-6-[(2-piperidine-1-ylethyl)thio]-2H-
Antimicrobial and antifungal test
The investigation of antimicrobial and antifungal activity of compounds 2.1-2.8 and 3.1-3.22 was carried out with the stiff plate agar diffusion method against Escherichia coli, Staphylococcus aureus, Mycobacterium luteum, Candida tenuis and Aspergillus niger. The amount of microbial cells was 109 c.f.u./mL. Incubation period of bacteria was 24 h at 35°C, yeast -48 to 72 h at 28-30°C. Antibiotics vancomicin, oxacillin, nystatin were used as standards. The bacterial cultures, standards and the obtained substances were streaked across grooves at 5 mg/mL concentration, and then allowed to diffuse in the agar nutrient plate. The antimicrobial effect and degree of activity of the tested compounds were evaluated by measuring of the inhibition zone diameters (low sensitive: 11-15 mm; sensitive: 16-25 mm; highly sensitive >25 mm). All experiments were repeated three times.
Cytotoxic activity against malignant human tumor cells
Primary anticancer assay was performed at human tumor cell lines panel derived from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda [24] [25] [26] [27] [28] [29] . Tested compounds were added to the culture at a single concentration (10 −5 M) and the cultures were incubated for 48 h. End point determinations were made with a protein binding dye, sulforhodamine B (SRB). Results for each tested compound were reported as the percent of growth of the treated cells when compared to the untreated control cells. The percentage growth was evaluated spectrophotometrically versus controls not treated with test agents. The cytotoxic and/or growth inhibitory effects of the most active selected compounds were tested in vitro against the full panel of about 60 human tumor cell lines at 10-fold dilutions of five concentrations ranging from 10 −4 to 10 −8 M. A 48-h continuous drug exposure protocol was followed and an SRB protein assay was used to estimate cell viability or growth. Using the seven absorbance measurements [time zero, (T z ), control growth in the absence of drug (C), and test growth in the presence of drug at the five concentration levels (T i )], the percentage growth was calculated at each of the drug concentrations levels. Percentage growth inhibition was calculated as:
for concentrations for which T i ≥ T z , T i − T z T z ×100 for concentrations for which T i < T z .
Three dose response parameters were calculated for each compound. Growth inhibition of 50% (GI 50 ) was calculated from [(T i − T z )/(C − T z )] × 100 = 50, which is the drug concentration resulting in a 50% lower net protein increase in the treated cells (measured by SRB staining) as compared to the net protein increase seen in the control cells. The drug concentration resulting in total growth inhibition (TGI) was calculated from T i = T z . The LC 50 (concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) indicating a net loss of cells following treatment was calculated from [(T i − T z )/T z ] ×100 = -50. Values were calculated for each of these three parameters if the level of activity was reached; however, if the effect was not reached or was exceeded, the value for that parameter was expressed as greater or less than the maximum or minimum concentration tested. The log GI 50 , log TGI, log LC 50 were then determined, defined as the mean of the log's of the individual GI 50 , TGI, LC 50 values. The lowest values were obtained
Conclusion
In the present paper, 22 new 6-{[ω-(dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones were described. Six of the synthesized compounds were tested for anticancer activity and most of them inhibited the growth of the leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancers cell lines. In conclusion, these preliminary results allowed identification of the most active compounds 3.14, 3.16 and 3.18. The latter 6-{[2-(diethylamino)ethyl]thio}-3-(4-methoxyphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.18) could be prospective antitumor agent (log GI 50 =−5,69 and log TGI=−5.14) with the selective influence on the colon cancer cell lines. The obtained results prove the necessity for further investigations to clarify the features underlying the antitumor potential of the tested compounds.
